AGTC Applied Genetic Technologies Co

-0.10  -2%
Previous Close 5.45
Open 5.40
Price To book 0.83
Market Cap 96.71M
Shares 18,076,000
Volume 166,816
Short Ratio 2.57
Av. Daily Volume 146,530

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 continues to enroll - May 2017.
AAV Gene Therapy
CNGB3 Achromatopsia
Phase 1/2 data due summer of 2017.
X-linked retinoschisis (XLRS)

Latest News

  1. AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked Retinitis Pigmentosa at the American Society of Gene and Cell Therapy 20th Annual Meeting
  2. Applied Genetic Technologies posts 3Q loss
  3. AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2017
  4. Investor Network: Applied Genetic Technologies Corp. to Host Earnings Call
  5. AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  6. AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 10, 2017
  7. ETFs with exposure to Applied Genetic Technologies Corp. : May 1, 2017
  8. AGTC to Present at the 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
  9. ETFs with exposure to Applied Genetic Technologies Corp. : April 5, 2017
  10. Applied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q2, 2017 By the Numbers : March 15, 2017
  11. Perrigo Launches First to Market OTC Equivalent of Rogaine
  12. Applied Genetic Technologies (AGTC) Shares March Higher, Can It Continue?
  13. AGTC to Present at the 29th Annual ROTH Conference on March 14, 2017
  14. Tenet Healthcare (THC) to Divest Operations to Amedisys
  15. Applied Genetic Technologies posts 2Q profit
  16. Implied Volatility Surging for Applied Genetic Technologies (AGTC) Stock Options